Adial Pharmaceuticals (ADIL) Operating Income (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Operating Income of -$2.0 million for Q1 2026, up 66.16% sequentially from -$5.9 million in Q3 2025, and up 11.72% YoY from -$1.8 million in Q1 2025.
Adial Pharmaceuticals (ADIL) Operating Income (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Operating Income for 10 years, with the latest figure at -$2.0 million in Q1 2026.
- Quarterly Operating Income rose 11.72% year-over-year to -$2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.0 million (down 10.22% YoY) and the FY2025 annual result came in at -$7.8 million, up 5.85% from the prior year.
- Operating Income grew to -$2.0 million in Q1 2026 per ADIL's latest filing, from -$5.9 million in the prior quarter.
- Over five years, Operating Income peaked at -$894649.0 in Q4 2023 and troughed at -$6.3 million in Q3 2024.
- A 5-year average of -$2.6 million and a median of -$2.3 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income soared 65.56% in 2023, then slumped 367.16% in 2024.
- Over 5 years, Operating Income stood at -$2.6 million in 2022, then jumped by 65.56% to -$894649.0 in 2023, then slumped by 42.25% to -$1.3 million in 2024, then sank by 364.72% to -$5.9 million in 2025, then surged by 66.16% to -$2.0 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$2.0 million, -$5.9 million, and -$2.8 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - | 133.12 Mn |
| 10 | Adial Pharmaceuticals | 27.08 Mn | 27.08 Mn | - | -52.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.00 Mn |
| Sep 30, 2025 | -5.91 Mn |
| Jun 30, 2025 | -2.82 Mn |
| Mar 31, 2025 | -2.27 Mn |
| Dec 31, 2024 | -1.27 Mn |
| Sep 30, 2024 | -6.34 Mn |
| Jun 30, 2024 | -1.92 Mn |
| Mar 31, 2024 | -1.28 Mn |
| Dec 31, 2023 | -894,649.00 |
| Sep 30, 2023 | -1.36 Mn |
| Jun 30, 2023 | -1.48 Mn |
| Mar 31, 2023 | -2.27 Mn |
| Dec 31, 2022 | -2.60 Mn |
| Sep 30, 2022 | -2.55 Mn |
| Jun 30, 2022 | -3.24 Mn |
| Mar 31, 2022 | -3.06 Mn |
| Dec 31, 2021 | -5.98 Mn |
| Sep 30, 2021 | -4.06 Mn |
| Jun 30, 2021 | -4.40 Mn |
| Mar 31, 2021 | -4.84 Mn |